Year-end Sale % OFF 
Abstract
RRecently, highly potent and RET-specific inhibitors were translated to the clinic. In Japan, A RET-specific inhibitor, selpercatinib, has been implemented for RET-fusion positive non-small cell lung carcinoma in December, 2021. The RET gene is an oncogene that encodes a receptor-type tyrosine kinase, and actually functions as a driver gene for various cancer types other than lung cancer. In fact, clinical trials of RET inhibitors have confirmed their therapeutic effects in various cancer types, including pancreatic, breast, and ovarian cancers, and it is expected that they will be implemented as a tumor-agnostic treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
